Abstract Objective To develop a Canadian consensus document on maternal screening for
fetal aneuploidy (eg, Down syndrome and trisomy 18) in singleton pregnancies. Options …

Abstract Objective: To develop a Canadian consensus document with recommendations on
maternal screening for fetal aneuploidy (eg, Down syndrome and trisomy 18) in pregnancy …

Objective This study aimed to assess the efficacy of first‐trimester aneuploidy screening in a
single clinical setting. Methods Maternal age, nuchal translucency, and maternal serum …

Background Screening for aneuploid pregnancies is routinely performed after 15 weeks of
gestation and has a sensitivity of approximately 65 percent, with a false positive rate of 5 …

There have been tremendous advancements over the past three decades in prenatal
screening for aneuploidy and we have changed our practice from screening by maternal …

The recent introduction of clinical tests to detect fetal aneuploidy by analysis of cell-free DNA
in maternal plasma represents a tremendous advance in prenatal diagnosis and the …

Noninvasive prenatal testing (NIPT) refers to recently developed genetic tests of the
maternal serum that allow higher detection rates of trisomy 21 and other chromosomal …

OBJECTIVE: We sought to assess performance of noninvasive prenatal testing for fetal
trisomy in a routinely screened first-trimester pregnancy population. STUDY DESIGN: This …

BACKGROUND Definitive prenatal diagnosis of chromosome abnormalities through the
analysis of amniocytes or chorionic villus samples (CVS) is an accepted part of prenatal …

The author discusses non-invasive prenatal testing (NIPT) for fetal aneuploidy with the use
of maternal plasma DA sequencing. He mentions the study by G. Ashoor and colleagues …